<SEC-DOCUMENT>0001564590-19-007678.txt : 20190314
<SEC-HEADER>0001564590-19-007678.hdr.sgml : 20190314
<ACCEPTANCE-DATETIME>20190314085246
ACCESSION NUMBER:		0001564590-19-007678
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190314
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190314
DATE AS OF CHANGE:		20190314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		19679844

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mygn-8k_20190314.htm
<DESCRIPTION>8-K MYPATH PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mygn-8k_20190314.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="font-weight:normal;">&nbsp;&nbsp;</font>March 14, 2019</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MYRIAD GENETICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0-26642</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">87-0494517</p></td>
</tr>
<tr>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">320 Wakara Way</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Salt Lake City, Utah 84108</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) (Zip Code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant's telephone number, including area code: <font style="letter-spacing:-0.1pt;">(801) 584-3600</font></p>
<p style="margin-top:6pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="font-style:italic;">see </font>General Instruction A.2. below):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="letter-spacing:-0.15pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:MS Mincho;">&#9744;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:MS Mincho;">&#9744;</font></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 7.01</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Regulation FD Disclosure</font></p></td></tr></table></div>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <font style="color:#000000;">March 14, 2019, Myriad Genetics, Inc. (&#8220;Myriad&#8221; or the &#8220;Company&#8221;) issued a press release announcing that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath&#174; Melanoma test.&nbsp;&nbsp;A copy of the press release announcing the LCD is furnished as Exhibit&#160;99.1 to this Current Report on Form 8-K and incorporated herein by reference.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication, including the exhibits attached hereto, contain &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These &#8220;forward-looking statements&#8221; are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 9.01</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:93%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mygn-ex991_6.htm"><font style="text-decoration:underline;">Press Release dated March 14, 2019.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibit(s) may contain hypertext links to information on our website or other parties&#8217; websites. The information on our website and other parties&#8217; websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 7.01 and in Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:44.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MYRIAD GENETICS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;March 14, 2019</p></td>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ R. Bryan Riggsbee</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Bryan Riggsbee</p></td>
</tr>
<tr>
<td valign="top"  style="width:55.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mygn-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mygn-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmrknciv14k1000001.jpg" title="" alt="" style="width:199px;height:80px;"><font style="text-decoration:underline;font-family:Arial;margin-left:36pt;"></font><font style="text-decoration:underline;font-size:22pt;font-family:Arial;">News Release</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:<font style="margin-left:36pt;">Ron RogersInvestor Contact:Scott Gleason</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">(801) 584-3065(801) 584-1143</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">rrogers@myriad.com</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">sgleason@myriad.com</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1D242A;font-size:12pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Myriad&#8217;s myPath<sup style="font-size:85%; vertical-align:top">&#174;</sup> Melanoma Test Receives Medicare Coverage </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:11pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Test Will Help Patients Receive a Definitive Diagnosis </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:11pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">for a Suspicious Skin Lesion Biopsy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SALT LAKE CITY, March 14, 2019 &#8211;<font style="font-weight:normal;"> Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced </font><font style="Background-color:#FFFFFF;color:#1D242A;font-weight:normal;">that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the </font><font style="Background-color:#FFFFFF;text-decoration:underline;font-weight:normal;">myPath<sup style="font-size:85%; vertical-align:top">&#174;</sup> Melanoma</font><font style="Background-color:#FFFFFF;color:#1D242A;font-weight:normal;"> test to help physicians provide a definitive diagnosis when a suspicious skin lesion</font><font style="font-weight:normal;"> is equivocal based upon histopathology</font><font style="Background-color:#FFFFFF;color:#1D242A;font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#1D242A;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#8220;We are excited that Palmetto has reviewed the extensive clinical dossier for the myPath Melanoma test and decided to cover the test for Medicare patients,&#8221; </font><font style="color:#000000;">said Vicki Fish, vice president of Dermatology, Myriad Genetics.&nbsp;&nbsp;&#8220;We look forward to </font><font style="Background-color:#FFFFFF;">making the myPath Melanoma test accessible to more patients so that they can obtain a definitive diagnosis and receive appropriate treatment and better health outcomes.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Melanoma is one of the fastest growing cancers in the United States and can strike people of all ages, races and skin types.&nbsp;&nbsp;More than one million skin biopsies are performed annually and approximately 15 percent of patients have an equivocal skin lesion.&nbsp;&nbsp;The myPath Melanoma test analyzes 23 genes and has proven to be highly accurate in multiple studies at distinguishing melanoma from benign moles (nevi).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#1D242A;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"> </font><font style="color:#000000;">&#8221;There</font><font style="Background-color:#FFFFFF;"> is strong demand among physicians for an objective genetic test to be used as an adjunct to historical approaches for diagnosis,&#8221; </font><font style="color:#000000;">said Loren Clarke, M.D., board certified dermatopathologist and medical director, Dermatology, Myriad Genetics.&nbsp;&nbsp;&#8220;The myPath Melanoma test has enormous potential to help patients because an appropriate treatment plan begins with an accurate and definitive diagnosis.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates about myPath Melanoma.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:11pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">About Melanoma</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the <font style="text-decoration:underline;color:#000000;">American Cancer Society</font>, approximately 96,480 Americans are expected to be diagnosed with melanoma this year.<font style="color:#000000;">&nbsp;&nbsp;Early and accurate diagnosis of melanoma is critical for long-term survival.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">About Myriad myPath<sup style="font-size:85%; vertical-align:top">&#174;</sup> Melanoma </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myriad myPath Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The test measures the expression of 23 genes and accurately distinguishes melanoma from benign nevi.&nbsp;&nbsp;For more information visit: <font style="text-decoration:underline;">www.mypathmelanoma.com/</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About <font style="text-decoration:underline;">Myriad Genetics</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.&#160; Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.&#160; Myriad is focused on five strategic imperatives:&#160; build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020.&#160; For more information on how Myriad is making a difference, please visit the Company's website: <font style="text-decoration:underline;">www.myriad.com</font><font style="text-decoration:underline;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Myriad, the Myriad logo, BART, BRAC<font style="font-style:italic;">Analysis</font>, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="Background-color:#FFFFFF;">Safe Harbor Statement</font><font style="font-weight:normal;"><br /></font><font style="Background-color:#FFFFFF;font-weight:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the </font><font style="Background-color:#FFFFFF;color:#1D242A;font-weight:normal;">final LCD for the myPath<sup style="font-size:85%; vertical-align:top">&#174;</sup> Melanoma test; the ability of the </font><font style="text-decoration:none;Background-color:#FFFFFF;color:#auto;font-weight:normal;">myPath<sup style="font-size:85%; vertical-align:top">&#174;</sup> Melanoma</font><font style="Background-color:#FFFFFF;font-weight:normal;"> </font><font style="Background-color:#FFFFFF;color:#1D242A;font-weight:normal;">test to help physicians provide a definitive diagnosis when a suspicious lesion</font><font style="font-weight:normal;"> is equivocal based upon histopathology</font><font style="font-weight:normal;">; </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;color:#1D242A;font-weight:normal;">making the myPath Melanoma accessible to more patients so that they can obtain an accurate diagnosis, receive appropriate treatment and achieve the best health outcomes;</font><font style="font-weight:normal;"> </font><font style="Background-color:#FFFFFF;font-weight:normal;">strong demand among p</font><font style="Background-color:#FFFFFF;font-weight:normal;">hysicians for an objective genetic test to be used as an adjunct to historical approaches for diagnosis; </font><font style="font-weight:normal;">the myPath Melanoma test&#8217;s enormous potential to help patients because an appropriate treatment plan starts with an accurate and definitive diagnosis</font><font style="font-weight:normal;">;</font><font style="Background-color:#FFFFFF;font-weight:normal;"> </font><font style="Background-color:#FFFFFF;font-weight:normal;">and the Company's strategic directives under the caption "About Myriad Genetics."&#160; These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause ac</font><font style="Background-color:#FFFFFF;font-weight:normal;">tual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and ph</font><font style="Background-color:#FFFFFF;font-weight:normal;">armaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurer</font><font style="Background-color:#FFFFFF;font-weight:normal;">s&#8217; reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may </font><font style="Background-color:#FFFFFF;font-weight:normal;">be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic test</font><font style="Background-color:#FFFFFF;font-weight:normal;">s and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and an</font><font style="Background-color:#FFFFFF;font-weight:normal;">y future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic tes</font><font style="Background-color:#FFFFFF;font-weight:normal;">ting in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability</font><font style="Background-color:#FFFFFF;font-weight:normal;"> to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license </font><font style="Background-color:#FFFFFF;font-weight:normal;">or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or t</font><font style="Background-color:#FFFFFF;font-weight:normal;">hat third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws co</font><font style="Background-color:#FFFFFF;font-weight:normal;">vering our molecular diagnostic tests and </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;font-weight:normal;">pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Path</font><font style="Background-color:#FFFFFF;font-weight:normal;">ology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;&#160; the risk that we</font><font style="Background-color:#FFFFFF;font-weight:normal;"> will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2018, w</font><font style="Background-color:#FFFFFF;font-weight:normal;">hich has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.&#160; All information in this press release is as of the </font><font style="Background-color:#FFFFFF;font-weight:normal;">date of the release, and Myriad undertakes no duty to update this information unless required by law.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gmrknciv14k1000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmrknciv14k1000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 ,@# 2(  A$! Q$!_\0
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M(ZK#*D:D'!("D=J] %<)\5O^17A_Z^5_]!-8IW9LU9'6Z22=$L"3DFVCY/\
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MO_0!4=[;Z-KT$%M>16]Y%,OGQ1R#<& Q\P_[Z'YT_3M3TRY/V/3YXW\A=NQ
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
